Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Galapagos N.V. buy melinda

Start price
€43.25
10.05.16 / 50%
Target price
€75.00
10.11.16
Performance (%)
29.18%
End price
€55.87
10.11.16
Summary
This prediction ended on 10.11.16 with a price of €55.87. The prediction had a final performance of 29.18%. melinda has a follow-up prediction for Galapagos N.V. where he still thinks Galapagos N.V. is a Buy. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Galapagos N.V. -3.108% -3.108% -12.042% -53.477%
iShares Core DAX® 2.149% 5.415% 21.385% 22.595%
iShares Nasdaq 100 0.838% 1.926% 44.386% 55.330%
iShares Nikkei 225® 1.143% 2.887% 27.641% 9.481%
iShares S&P 500 1.265% 3.698% 33.327% 49.646%

According to melinda what are the pros and cons of Galapagos N.V. for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Cons

Comments by melinda for this prediction

In the thread Galapagos N.V. diskutieren
Prediction Buy
Perf. (%) 29.18%
Target price 75.000
Change
Ends at 10.11.16

BULL



Galapagos startet Phase 1 mit dem Medikamentenkandidaten für GLPG2451   Cystische Fibrose (CF, oder zystische Fibrose). Das Unternehmen erhält im Gegenzug eine Meilensteinzahlung von 10 Millionen   Dollar   für die jüngste umfassende Kooperationsvereinbarung mit Abbvie.   Wir bekräftigen unser Board mit einem empfohlenen Verkaufspreis von EUR 75. Diese objektive Meinung spekulativ ist.   GLPG2451 ist die zweite nach GLPG1837 potentiator.   Für GLPG1837, jetzt Galapagos Rekrutierung   Saphira Patienten für die explorative Phase - 2 - Programm.   Die Ergebnisse dieses Programms werden in der zweiten Hälfte des Jahres 2016 erwartet.   Galapagos und Abbvie arbeiten an einer Kombinationstherapie 90% der Patienten zur Behandlung mit   Cystische Fibrose.   Die Unternehmen entwickeln sich mehrere Kandidaten und Sicherungen für alle drei Komponenten, die so genannte potentiator und Korrektor


Prediction Buy
Perf. (%) 29.18%
Target price 75.000
Change
Ends at 10.11.16

(Laufzeit überschritten)

Current prediction by melinda for Galapagos N.V.

buy
Galapagos N.V.

Start price
Target price
Perf. (%)
€31.69
12.03.24
€36.00
12.03.25
-5.96%
13:13

Could be worthwhile Investment >10% per year

Stopped prediction by melinda for Galapagos N.V.

buy
Galapagos N.V.

Start price
Target price
Perf. (%)
€45.08
13.10.21
€46.00
13.10.22
-0.18%
14.10.22

Could be worthwhile Investment >10% per year
buy
Galapagos N.V.

Start price
Target price
Perf. (%)
€65.08
09.06.21
€70.00
09.06.22
-30.73%
13.10.21

Could be worthwhile Investment >10% per year
buy
Galapagos N.V.

Start price
Target price
Perf. (%)
€115.20
11.09.20
-
04.11.21
-43.51%
09.06.21

Could be worthwhile Investment >10% per year
buy
Galapagos N.V.

Start price
Target price
Perf. (%)
€144.05
19.09.19
-
11.09.20
-20.03%
11.09.20

Could be worthwhile Investment >10% per year
buy
Galapagos N.V.

Start price
Target price
Perf. (%)
€71.55
10.08.17
€75.00
01.11.17
20.10%
01.11.17

Could be worthwhile Investment >10% per year
buy
Galapagos N.V.

Start price
Target price
Perf. (%)
€71.55
10.08.17
€75.00
01.11.17
20.10%
01.11.17

Could be worthwhile Investment >10% per year